National Health (Listed drugs on F1 or F2) Amendment Determination 2019 (No. 4) (PB 33 of 2019) (Cth)

PB 33 of 2019

National Health (Listed drugs on F1 or F2) Amendment Determination 2019 (No. 4)

National Health Act 1953

I, SEAN LANE, Acting Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this determination under subsection 85AB(1) of the National Health Act 1953.

Dated            29  April 2019

SEAN LANE

Acting Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

Part 1         Preliminary

1. Name of Determination

(1)   This Determination is the National Health (Listed drugs on F1 or F2) Amendment Determination 2019 (No. 4).

(2)   This Determination may also be cited as PB 33 of 2019.

1. Commencement

This Determination commences on 1 May 2019.

1. Amendment of National Health (Listed drugs on F1 or F2) Determination 2010

Schedule 1 amends the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010).

Schedule 1             Amendments

(Section 3)

[1]     Schedule 1, after item dealing with Aurothiomalate

Insert

Avelumab

[2]     Schedule 1, after item dealing with Clobetasol

Omit

Clodronic acid

[3]     Schedule 1, after item dealing with Indacaterol

Insert

Inotuzumab ozogamicin

[4]     Schedule 1, after item dealing with Paclitaxel, nanoparticle albumin-bound

Insert

Palbociclib